Biosino Bio-Technology and Science Incorporation (HKG:8247)
Hong Kong · Delayed Price · Currency is HKD 4.280
+0.190 (4.65%)
At close: Jan 30, 2026
HKG:8247 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 225.06 | 263.07 | 289.07 | 373.07 | 348.23 | 325.26 | |
Revenue Growth (YoY) | -20.69% | -9.00% | -22.52% | 7.13% | 7.06% | -18.16% |
Cost of Revenue | 137.81 | 154.67 | 161.71 | 226.79 | 204.63 | 214.7 |
Gross Profit | 87.25 | 108.4 | 127.37 | 146.28 | 143.59 | 110.56 |
Selling, General & Admin | 96.29 | 106.6 | 110.4 | 99.67 | 93.27 | 94.52 |
Research & Development | 29.87 | 33.42 | 35.81 | 26.87 | 24.94 | 27.84 |
Operating Expenses | 130.9 | 145.69 | 146.78 | 126.54 | 118.22 | 122.36 |
Operating Income | -43.65 | -37.29 | -19.41 | 19.74 | 25.38 | -11.8 |
Interest Expense | -9.55 | -9.3 | -6.4 | -6.82 | -10.57 | -11.32 |
Interest & Investment Income | 1.66 | 1.66 | 0.33 | 0.34 | 0.22 | 10.91 |
Earnings From Equity Investments | -0.35 | -0.42 | 12.35 | 6.53 | 1.57 | 2.13 |
Other Non Operating Income (Expenses) | -1.41 | -1.41 | -3.88 | -1.08 | -10.07 | 3.01 |
EBT Excluding Unusual Items | -53.29 | -46.75 | -17.02 | 18.71 | 6.54 | -7.06 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 2.82 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.63 |
Asset Writedown | -12.97 | -12.97 | -0.59 | -0.19 | -0.13 | 5.42 |
Other Unusual Items | - | - | - | - | - | 0.36 |
Pretax Income | -66.27 | -59.72 | -17.61 | 18.52 | 6.41 | 2.16 |
Income Tax Expense | -4.79 | -2.83 | 1.63 | 4.31 | 3.25 | 2.86 |
Earnings From Continuing Operations | -61.48 | -56.89 | -19.24 | 14.2 | 3.16 | -0.71 |
Net Income to Company | -61.48 | -56.89 | -19.24 | 14.2 | 3.16 | -0.71 |
Minority Interest in Earnings | 14.15 | 14.36 | 7.59 | -6.1 | -4.3 | 3.42 |
Net Income | -47.33 | -42.53 | -11.65 | 8.11 | -1.14 | 2.72 |
Net Income to Common | -47.33 | -42.53 | -11.65 | 8.11 | -1.14 | 2.72 |
Shares Outstanding (Basic) | 145 | 145 | 145 | 145 | 145 | 145 |
Shares Outstanding (Diluted) | 145 | 145 | 145 | 145 | 145 | 145 |
EPS (Basic) | -0.33 | -0.29 | -0.08 | 0.06 | -0.01 | 0.02 |
EPS (Diluted) | -0.33 | -0.29 | -0.08 | 0.06 | -0.01 | 0.02 |
Free Cash Flow | 9.78 | 11.36 | -22.91 | 28.19 | 45.15 | -2.39 |
Free Cash Flow Per Share | 0.07 | 0.08 | -0.16 | 0.20 | 0.31 | -0.02 |
Gross Margin | 38.77% | 41.21% | 44.06% | 39.21% | 41.23% | 33.99% |
Operating Margin | -19.39% | -14.17% | -6.72% | 5.29% | 7.29% | -3.63% |
Profit Margin | -21.03% | -16.17% | -4.03% | 2.17% | -0.33% | 0.84% |
Free Cash Flow Margin | 4.35% | 4.32% | -7.92% | 7.56% | 12.97% | -0.73% |
EBITDA | -29.97 | -22.7 | -2.35 | 40.92 | 49.93 | 9.45 |
EBITDA Margin | -13.31% | -8.63% | -0.81% | 10.97% | 14.34% | 2.90% |
D&A For EBITDA | 13.68 | 14.59 | 17.06 | 21.18 | 24.55 | 21.24 |
EBIT | -43.65 | -37.29 | -19.41 | 19.74 | 25.38 | -11.8 |
EBIT Margin | -19.39% | -14.17% | -6.72% | 5.29% | 7.29% | -3.63% |
Effective Tax Rate | - | - | - | 23.30% | 50.68% | 132.76% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.